Immuneering Corporation (IMRX)
Total Valuation
Immuneering has a market cap or net worth of $267.80 million. The enterprise value is $167.11 million.
| Market Cap | 267.80M |
| Enterprise Value | 167.11M |
Important Dates
The next earnings date is Tuesday, May 9, 2023, before market open.
| Estimated Earnings Date | May 9, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Immuneering has 26.44 million shares outstanding. The number of shares has increased by 93.84% in one year.
| Shares Outstanding | 26.44M |
| Shares Change (YoY) | +93.84% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 30.53% |
| Owned by Institutions (%) | 44.81% |
| Float | 13.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 844.92 |
| Forward PS | 477.81 |
| PB Ratio | 2.44 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 527.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.50, with a Debt / Equity ratio of 0.04.
| Current Ratio | 13.50 |
| Quick Ratio | 13.10 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -97.70%.
| Return on Equity (ROE) | -39.70% |
| Return on Assets (ROA) | -36.70% |
| Return on Capital (ROIC) | -97.70% |
| Revenue Per Employee | $4,283 |
| Profits Per Employee | -$682,616 |
| Employee Count | 74 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.77% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | +30.77% |
| 50-Day Moving Average | 5.48 |
| 200-Day Moving Average | 7.25 |
| Average Volume (30 Days) | 43,618 |
Short Selling Information
The latest short interest is 863,461, so 3.27% of the outstanding shares have been sold short.
| Short Interest | 863,461 |
| Short Previous Month | 829,271 |
| Short % of Shares Out | 3.27% |
| Short % of Float | 6.20% |
| Short Ratio (days to cover) | 21.86 |
Income Statement
In the last 12 months, Immuneering had revenue of $316,952 and -$50.51 million in losses. Loss per share was -$1.91.
| Revenue | 316,952 |
| Gross Profit | 158,830 |
| Operating Income | -51.74M |
| Pretax Income | -50.51M |
| Net Income | -50.51M |
| EBITDA | -49.72M |
| EBIT | -50.51M |
| Loss Per Share | -$1.91 |
Balance Sheet
The company has $105.52 million in cash and $4.84 million in debt, giving a net cash position of $100.68 million or $3.81 per share.
| Cash & Cash Equivalents | 105.52M |
| Total Debt | 4.84M |
| Net Cash | 100.68M |
| Net Cash Per Share | $3.81 |
| Equity / Book Value | 109.85M |
| Book Value Per Share | 4.16 |
| Working Capital | 100.69M |
Cash Flow
In the last 12 months, operating cash flow was -$44.10 million and capital expenditures -$742,483, giving a free cash flow of -$44.84 million.
| Operating Cash Flow | -44.10M |
| Capital Expenditures | -742,483 |
| Free Cash Flow | -44.84M |
| FCF Per Share | -$1.70 |
Margins
Gross margin is 50.11%, with operating and profit margins of -16,325.77% and -15,937.29%.
| Gross Margin | 50.11% |
| Operating Margin | -16,325.77% |
| Pretax Margin | -15,937.29% |
| Profit Margin | -15,937.29% |
| EBITDA Margin | -15,685.90% |
| EBIT Margin | -15,937.29% |
| FCF Margin | -14,148.44% |
Dividends & Yields
Immuneering does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -18.86% |
| FCF Yield | -16.75% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -93.84% |
| Shareholder Yield | -93.84% |
Analyst Forecast
The average price target for Immuneering is $16.32, which is 61.11% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.32 |
| Price Target Difference | 61.11% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 260.76% |
| EPS Growth Forecast (5Y) | -20.23% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |